Zymeron Corporation
NC
- UEI
- GAMMMRQ6QMN1
- CAGE
- 7MVB7
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 400 Park Offices Dr #311, Research Triangle Park, NC 27709, USA
- Website
- zymeron.com
- Founded
- 2016
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $3,468,978 |
| FY2023 | $3,751,781 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Advanced portable low temperature plasma device for chronic wound disinfection and healing | Office of Science | $200,000 |
Similar vendors
About the company
Zymeron Corporation is a minority-owned, for-profit biotechnology company located in Research Triangle Park, North Carolina, specializing in innovative medical research and development solutions for federal agencies. Registered in SAM.gov since 2016, the company focuses on delivering cutting-edge technologies across multiple domains including infectious disease diagnostics, drug delivery systems, radiation exposure treatments, and medical countermeasures. As a small business participant in federal contract and grant programs, Zymeron has consistently secured awards from defense and civilian agencies through mechanisms like the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs.
Zymeron's federal contract awards demonstrate extensive expertise in developing advanced medical technologies for multiple federal agencies, particularly the Department of Defense and Department of Health and Human Services. The company has secured numerous prime contracts focused on developing innovative solutions such as rapid point-of-care diagnostic tests for diseases like HIV, hepatitis C, and tuberculosis, novel antibiotic treatments for drug-resistant infections, and medical technologies addressing critical healthcare challenges. These contracts, predominantly set aside for small businesses, have ranged from $150,000 to $3 million and span research areas including wound infection diagnostics, hemorrhagic shock treatments, radiation exposure countermeasures, and advanced drug delivery systems. Major contracting agencies include the Defense Health Agency, National Institutes of Health, National Cancer Institute, National Institute of Allergy and Infectious Diseases, and various Department of Defense research commands.
Zymeron's federal grant awards, while more limited, align closely with its contract work and emphasize advanced medical research and development. The company was awarded a $200,000 project grant from the U.S. Department of Energy Office of Science to develop an advanced portable low-temperature plasma device for chronic wound disinfection and healing. This grant, awarded in July 2023 with a completion date of April 2024, represents the company's commitment to innovative medical solutions that can potentially transform healthcare technologies. The grant falls under the Office of Science Financial Assistance Program and demonstrates Zymeron's ability to secure funding for cutting-edge research that addresses critical medical challenges across various federal scientific agencies.
Quick answers
Is Zymeron Corporation registered in SAM.gov?
Yes. Zymeron Corporation's SAM.gov registration is active through June 8, 2027.
How much has Zymeron Corporation received in federal contracts?
Federal contracts obligated $7,220,759 to Zymeron Corporation in fiscal years 2023 through 2027.
What is Zymeron Corporation's most recent federal award?
Zymeron Corporation's most recent federal contract award is DHA sbir direct phase II H2D-0243 rapid sample processing device to support battlefield wound infection diagnostics (HT942524C0057), from Defense Health Agency, on September 20, 2024.
On GovTribe
See Zymeron Corporation's full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors